| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3666 |
| Trial ID | NCT06138132 |
| Disease | Multiple Sclerosis |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KYV-101 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis |
| Year | 2024 |
| Country | United States |
| Company sponsor | Stanford University |
| Other ID(s) | 70408 |
| Cohort 1 | |||||||||||
|
|||||||||||